We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




CCN1 Analyzed as a Biomarker for Breast Cancer Detection

By LabMedica International staff writers
Posted on 14 Sep 2021
Print article
Image: The NanoQuant infinite M200 pro reader is an easy-to-use multimode plate reader family (Photo courtesy of Neotec Scientific Instrumentation)
Image: The NanoQuant infinite M200 pro reader is an easy-to-use multimode plate reader family (Photo courtesy of Neotec Scientific Instrumentation)
Breast cancer is the most frequent malignancy in women with 1.7 million new cases and over 500,000 deaths worldwide in 2016. Early detection of cancer is believed to be crucial in reducing cancer death. Despite recent progress in liquid biopsy technologies, early blood-based detection of breast cancer is still a challenge.

Liquid biopsy includes, besides circulating tumor cells, subcellular components like DNA, RNA, and/or proteins that are released by tumor cell deposits into the blood. In particular, circulating cell-free DNA has received great attention. The combination of circulating tumor DNA with circulating tumor-associated proteins has opened a new avenue for cancer screening.

A large team of Medical Scientists at the University Medical Centre Hamburg-Eppendorf (Hamburg, Germany) and their colleagues analyzed secretion of the protein cellular communication network factor 1 (CCN1, formerly cysteine-rich angiogenic inducer 61) in breast cancer cell lines by an enzyme-linked immunosorbent assay (ELISA). Soluble CCN1 in the plasma of 544 patients with breast cancer and 427 healthy controls was analyzed by ELISA.

Samples from patients with benign breast diseases and from 127 patients with acute heart diseases were investigated as additional non-cancer controls. The CCN1 ELISA was performed using fresh blood plasma or archived sample and diluted in Dulbecco’s Modified Eagle Medium with 10% fetal calf serum. The detection was done using the NanoQuant infinite M200 pro reader (Tecan, Männedorf, Switzerland). Samples with a CCN1 concentration equal to or higher than the lower limit of detection were considered as positive in this work.

The investigators reported that CCN1 was frequently secreted by breast cancer cell lines into the extracellular space. Subsequent analysis of clinical blood samples from patients with breast cancer and age-adjusted healthy controls revealed an overall specificity of 99.0% and sensitivity of 80.0% for cancer detection. Remarkably, 81.5% of small T1 cancers were already CCN1-positive, while CCN1 concentrations in patients with benign breast lesions were below the threshold for breast cancer detection.

Generally, the CCN1 concentrations in the plasma of patients with other diseases such as acute kidney injury, sepsis, or autoimmune diseases such as rheumatoid arthritis were <0.5 ng/mL and therefore below the critical CCN1 concentration of our classifier of 0.69 ng/mL. Similarly, CCN1 concentrations of 0.62 ng/mL were found in coronary artery disease patients, but increased CCN1 concentrations were detected in the subgroup of patients with acute myocardial infarction with less than six hours after the onset of chest pain.

The authors concluded that with regard to clinical application, circulating CCN1 appears to be a diagnostically sensitive biomarker for early detection of breast cancer and can be therefore included in liquid biopsy panels encompassing other proteins or cell-free DNA. The study published on August 30, 2021 in the journal Clinical Chemistry.

Related Links:
University Medical Centre Hamburg-Eppendorf
Tecan


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.